BioCancell Ltd

Location:

1/3 High-Tech Village Givat RamJerusalemJerusalem9139102Israel View Map

Revenue:

$1.6 Million

Employees:

8

SIC Codes:

2834, 3721

NAICS Codes:

325412, 541711

Phone:

+972 2-548-6555

Fax:

+972 2-548-6550
More

Description:

BioCancell is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer-related diseases. Its most advanced product candidate, BC-819, is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). BC-819 will enter two Phase III confirmatory studies in the first half of 2016. BioCancell is also developing a second-generation drug, BC-821 for the systemic treatment of advanced malignant neoplasms. Preclinical studies of BC-821 have showed significant efficacy in different cancer animal models such as metastatic lung cancer and metastatic liver cancer. BioCancell's third product candidate, BC-830, is a "liquid biopsy," which is intended to replace invasive and costly cystoscopies for the follow-up of NMIBC patients. BioCancell's R&D activities build upon the research of Professor Abraham Hochberg of the Hebrew University of Jerusalem. Professor Hochberg isolated the human H19 gene and determined that the gene is expressed in over forty different forms of cancer. H19-based therapy combines a highly selective method of killing cancer cells with a strong safety profile. Each of BioCancell's product candidates relies on a proprietary H19 technology platform, with the potential to provide benefits that are competitive with existing cancer treatment methods.

Read More

Recently Updated profiles at this company

Chief Operating Officer

Account Manager

Founder and Chief Executive Officer

Senior Project Manager and Analytical Lab Manager

Browse ZoomInfo’s Directories